ABA-101 is under clinical development by Abata Therapeutics and currently in Phase I for Primary Progressive Multiple Sclerosis (PPMS). According to GlobalData, Phase I drugs for Primary Progressive Multiple Sclerosis (PPMS) have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ABA-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ABA-101 overview
ABA-101 is under development for the treatment of primary progressive multiple sclerosis and nonactive secondary progressive multiple sclerosis. The drug candidate comprises of autologous regulatory T (Treg) cells genetically engineered to express T cell receptor (TCR).
Abata Therapeutics overview
Abata Therapeutics (Abata) provides engineering regulatory T cells (Tregs) into transformational medicines to treat autoimmune and inflammatory diseases. The company’s pipeline products include ABA -101, and ABA – 202. Its pipeline candidates treat progressive multiple sclerosis and type 1 diabetes. Abata also offers treatment of autoimmune disease by engineering regulatory T cells (Tregs) as targeted therapies that stop immune-mediated destruction, restore homeostasis, and promote repair in affected tissues. The company was funded by Third Rock Ventures, Elevate Bio, Samsara Capital, Invus, lightspeed, T1D Fund, and other companies. Abata is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of ABA-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
